Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.
Blood Cancer Discov. 2022 Sep 6;3(5):374-377. doi: 10.1158/2643-3230.BCD-22-0090.
In this issue of Blood Cancer Discovery, Han and colleagues find that follicular lymphomas (FL) can be stratified into distinct classes with clinical and functional relevance based on their T-cell subset composition. Their findings further indicate that pairing of FL cell MHCII expression with specific T-cell markers may represent a useful diagnostic approach to select patients for particular immunotherapies or immune augmentation therapies independent of genetic profiling. See related article by Han et al., p. 428 (4).
在本期《血液癌症发现》中，韩等人发现滤泡性淋巴瘤（FL）可以根据其 T 细胞亚群组成分为具有临床和功能相关性的不同类别。他们的研究结果进一步表明，将 FL 细胞 MHCII 表达与特定 T 细胞标志物配对可能代表一种有用的诊断方法，可选择特定免疫疗法或免疫增强疗法的患者，而与基因谱无关。另见韩等人的相关文章，第 428 页（4）。
